SG11201906763RA - Pyrrolo [1,2-b] pyridazine derivatives - Google Patents
Pyrrolo [1,2-b] pyridazine derivativesInfo
- Publication number
- SG11201906763RA SG11201906763RA SG11201906763RA SG11201906763RA SG11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA SG 11201906763R A SG11201906763R A SG 11201906763RA
- Authority
- SG
- Singapore
- Prior art keywords
- gilead sciences
- foster city
- lakeside drive
- lakeside
- international
- Prior art date
Links
- NISJKLIMPQPAQS-UHFFFAOYSA-N pyrrolo[1,2-b]pyridazine Chemical class C1=CC=NN2C=CC=C21 NISJKLIMPQPAQS-UHFFFAOYSA-N 0.000 title abstract 3
- 229940127030 Foster Drugs 0.000 abstract 2
- 229940126656 GS-4224 Drugs 0.000 abstract 2
- 235000015241 bacon Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIP0 I PCT omit VIII °nolo HE Imo oimIE (10) International Publication Number WO 2018/152368 Al (51) International Patent Classification: CO7D 487/04 (2006.01) A61K 31/5377 (2006.01) CO7D 519/00 (2006.01) A61K 31/5383 (2006.01) A61K 31/5025 (2006.01) A61K 31/541 (2006.01) A61P 29/00 (2006.01) CO7D 453/00 (2006.01) A61K 31/506 (2006.01) (21) International Application Number: PCT/US2018/018431 (22) International Filing Date: 15 February 2018 (15.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/460,013 16 February 2017 (16.02.2017) US (71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US). (72) Inventors: BACON, Elizabeth, M.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). BRIZGYS, Gediminas; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). CHIN, El- bert; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Fos- ter City, CA 94404 (US). CHOU, Chienhung; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). COTTELL, Jeromy, J.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). LINK, John, O.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). TAYLOR, James, G.; c/ o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). TSE, Winston, C.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). WRIGHT, Nathan, E.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). YANG, Zheng-Yu; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). ZHANG, Jennifer, R.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). ZIPFEL, Sheila, M.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). (74) Agent: POLSTER, Philip, B. et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) 1-1 (54) Title: PYRROLO [1,2-B] PYRIDAZINE DERIVATIVES (57) : Provided is a compound of Formula (I), wherein the variable groups are defined HN ,Ri herein. R3 141\") H • I 1\r N - R4 N 1-1 0 .- 13 R7 R5 R6 (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460013P | 2017-02-16 | 2017-02-16 | |
| PCT/US2018/018431 WO2018152368A1 (en) | 2017-02-16 | 2018-02-15 | Pyrrolo [1,2-b] pyridazine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906763RA true SG11201906763RA (en) | 2019-08-27 |
Family
ID=61563476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906763RA SG11201906763RA (en) | 2017-02-16 | 2018-02-15 | Pyrrolo [1,2-b] pyridazine derivatives |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US10336762B2 (en) |
| EP (1) | EP3583105B1 (en) |
| JP (3) | JP6924267B2 (en) |
| KR (1) | KR102337055B1 (en) |
| CN (1) | CN110300754A (en) |
| AR (1) | AR110935A1 (en) |
| AU (2) | AU2018221812B2 (en) |
| BR (1) | BR102018002879A2 (en) |
| CA (1) | CA3050148A1 (en) |
| CL (1) | CL2019002306A1 (en) |
| CO (1) | CO2019008868A2 (en) |
| CR (1) | CR20190373A (en) |
| DK (1) | DK3583105T3 (en) |
| DO (1) | DOP2019000214A (en) |
| EA (1) | EA201991544A1 (en) |
| ES (1) | ES2975767T3 (en) |
| FI (1) | FI3583105T3 (en) |
| HU (1) | HUE065978T2 (en) |
| IL (1) | IL267979B (en) |
| JO (1) | JOP20180011A1 (en) |
| LT (1) | LT3583105T (en) |
| MA (1) | MA47500B1 (en) |
| MX (2) | MX2019009840A (en) |
| PE (1) | PE20191540A1 (en) |
| PH (1) | PH12019550128A1 (en) |
| PL (1) | PL3583105T3 (en) |
| PT (1) | PT3583105T (en) |
| RS (1) | RS65397B1 (en) |
| SA (1) | SA519402462B1 (en) |
| SG (1) | SG11201906763RA (en) |
| SI (1) | SI3583105T1 (en) |
| SM (1) | SMT202400146T1 (en) |
| TW (3) | TWI790674B (en) |
| UA (1) | UA124548C2 (en) |
| UY (1) | UY37608A (en) |
| WO (1) | WO2018152368A1 (en) |
| ZA (1) | ZA201905456B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3076613A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
| US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| KR102785432B1 (en) | 2018-07-09 | 2025-03-21 | 베링거잉겔하임베트메디카게엠베하 | Antiparasitic heterocyclic compounds |
| TWI721483B (en) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
| AU2019321267B2 (en) * | 2018-08-13 | 2022-07-14 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as IRAK4 inhibitors |
| WO2020036979A1 (en) * | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
| KR20210111252A (en) | 2018-11-30 | 2021-09-10 | 카이메라 쎄라퓨틱스 인코포레이티드 | IRAK disintegrants and uses thereof |
| AR118435A1 (en) | 2019-03-19 | 2021-10-06 | Boehringer Ingelheim Animal Health Usa Inc | AZA-BENZOTHIOPHENE AND AZA-BENZOFURAN COMPOUNDS AS ANTIHELMINTICS |
| CN111821308B (en) * | 2019-04-15 | 2021-10-08 | 中国科学院上海药物研究所 | Application of Leitengshu in the preparation of medicine for the treatment of non-alcoholic fatty liver disease |
| CN110755452B (en) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | Use of stem cells for treating osteoarthritis |
| CN110755451B (en) * | 2019-11-23 | 2021-07-06 | 博雅干细胞科技有限公司 | Mesenchymal stem cell composition for treating osteoarthritis and application thereof |
| JP2023509366A (en) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | IRAK dissolving agents and their uses |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN116249704A (en) | 2020-05-29 | 2023-06-09 | 勃林格殷格翰动物保健美国公司 | Heterocyclic compounds for insect repellent |
| TW202210483A (en) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Crystalline forms of irak degraders |
| EP4271664A1 (en) | 2020-12-30 | 2023-11-08 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| MX2023009527A (en) | 2021-02-15 | 2023-08-24 | Kymera Therapeutics Inc | Irak4 degraders and uses thereof. |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| TW202315632A (en) | 2021-08-18 | 2023-04-16 | 美商新銳思生物製藥股份有限公司 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
| KR20240110592A (en) | 2021-10-29 | 2024-07-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | IRAK4 degrader and its synthesis |
| WO2023073641A1 (en) | 2021-11-01 | 2023-05-04 | Boehringer Ingelheim Vetmedica Gmbh | Anthelmintic pyrrolopyridazine compounds |
| WO2023147594A2 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AR129535A1 (en) | 2022-06-21 | 2024-09-04 | Syngenta Crop Protection Ag | HETEROCYCLIC BICYCLIC CARBOXAMIDE DERIVATIVES MICROBIOCIDES |
| WO2024089191A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Microbiocidal heterobicyclic dihydrooxadiazine derivatives |
| TW202502770A (en) * | 2023-06-30 | 2025-01-16 | 美商基利科學股份有限公司 | Processes for making irak4 inhibitors |
| CN117849327A (en) * | 2024-03-06 | 2024-04-09 | 军科正源（北京）药物研究有限责任公司 | Methods for detecting a secukinumab-resistant antibody |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2458533C (en) | 2001-10-09 | 2011-01-04 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| CN101616910A (en) | 2006-09-07 | 2009-12-30 | 比奥根艾迪克Ma公司 | Indazole derivatives as interleukin 1 receptor associated kinase conditioning agent |
| DE102009033208A1 (en) | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | aminopyridine derivatives |
| JP2012254939A (en) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | Oxazole compound |
| RU2604062C2 (en) | 2010-07-13 | 2016-12-10 | Ф.Хоффманн-Ля Рош Аг | PYRAZOLO[1,5-a]PYRIMIDINE AND THIENO[3,2-b]PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK-4 |
| WO2012068546A1 (en) | 2010-11-19 | 2012-05-24 | Ligand Pharmaceuticals Incorporated | Heterocycle amines and uses thereof |
| AU2011347711B2 (en) | 2010-12-20 | 2017-02-02 | Merck Serono S.A. | Indazolyl triazole derivatives as IRAK inhibitors |
| EP2663312B1 (en) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2012129258A1 (en) | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| WO2013066729A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| JP6073910B2 (en) | 2011-11-09 | 2017-02-01 | キャンサー・リサーチ・テクノロジー・リミテッド | 5- (Pyridin-2-yl-amino) -pyrazine-2-carbonitrile compound and therapeutic use thereof |
| EP2802330A4 (en) | 2012-01-10 | 2015-10-21 | Nimbus Iris Inc | Irak inhibitors and uses thereof |
| ES2630705T3 (en) | 2012-01-13 | 2017-08-23 | Bristol-Myers Squibb Company | Triazolyl substituted pyridyl compounds useful as kinase inhibitors |
| US9242975B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| US9242976B2 (en) | 2012-01-13 | 2016-01-26 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| KR20150033716A (en) | 2012-07-10 | 2015-04-01 | 아레스 트레이딩 에스.에이. | Pyrimidine pyrazolyl derivatives |
| WO2014011906A2 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EP2903617B1 (en) | 2012-10-08 | 2019-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| WO2014058691A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| UY35126A (en) | 2012-11-08 | 2014-05-30 | Bristol Myers Squibb Co | EYE IS ALPHA |
| MX2015005562A (en) | 2012-11-08 | 2015-07-23 | Squibb Bristol Myers Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators. |
| ES2616812T3 (en) | 2012-11-08 | 2017-06-14 | Bristol-Myers Squibb Company | Pyridyl compounds substituted with bicyclic heterocycle useful as kinase modulators |
| BR112015009798A2 (en) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | alkyl amide substituted pyrimidine compounds useful in modulating il-12, il-23 and / or ifnalfa |
| CA2891655A1 (en) | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| AU2014205577A1 (en) | 2013-01-10 | 2015-05-28 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| BR112015018751A2 (en) | 2013-02-07 | 2017-07-18 | Merck Patent Gmbh | macrocyclic pyridazinone derivatives |
| WO2014121931A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
| US9617282B2 (en) | 2013-03-15 | 2017-04-11 | Biogen Ma Inc. | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| US20160166576A1 (en) | 2013-07-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
| MX2016003843A (en) | 2013-09-27 | 2017-02-15 | Nimbus Iris Inc | Irak inhibitors and uses thereof. |
| EP3066094B1 (en) | 2013-11-08 | 2020-01-08 | Takeda Pharmaceutical Company Limited | Pyrazole for the treatment autoimmune disorders |
| TWI667233B (en) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments |
| UY35935A (en) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | NICOTINAMIDE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND MODULATORS OF IRAK-4 |
| US10314841B2 (en) | 2014-01-09 | 2019-06-11 | Merck Patent Gmbh | Substituted pyrazoles as IRAK inhibitors |
| KR20160115933A (en) | 2014-01-10 | 2016-10-06 | 오리진 디스커버리 테크놀로지스 리미티드 | Indazole compounds as irak4 inhibitors |
| LT3805233T (en) | 2014-01-13 | 2024-05-10 | Aurigene Oncology Limited | (r) and (s) enantiomers of n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-carboxamide as irak4 inhibitors for the treatment of cancer |
| PL3536685T3 (en) | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| WO2015164374A1 (en) | 2014-04-22 | 2015-10-29 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2015193846A1 (en) | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
| WO2016011390A1 (en) | 2014-07-18 | 2016-01-21 | Biogen Ma Inc. | Irak4 inhibiting agents |
| EP3200788B1 (en) | 2014-09-30 | 2019-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US9969749B2 (en) | 2014-09-30 | 2018-05-15 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US9943516B2 (en) | 2014-09-30 | 2018-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| EP3200789B1 (en) | 2014-09-30 | 2019-11-06 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| JP6787892B2 (en) | 2014-11-20 | 2020-11-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Heteroaryl compounds as IRAK inhibitors and their use |
| JO3705B1 (en) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments |
| AU2016215185B2 (en) | 2015-02-05 | 2020-06-25 | Merck Patent Gmbh | Macrocyclic compounds as IRAK 1/4 inhibitors and uses thereof |
| CN107428765B (en) | 2015-02-06 | 2020-12-29 | 默克专利有限公司 | Pyridazinone macrocyclic compounds as IRAK inhibitors and their uses |
| EP3268003B1 (en) | 2015-03-12 | 2020-07-29 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
| US10329295B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrrolotriazine inhibitors of IRAK4 activity |
| EP3268004B1 (en) | 2015-03-12 | 2019-12-18 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of irak4 activity |
| EP3268367B8 (en) | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
| US9982000B2 (en) | 2015-04-22 | 2018-05-29 | Rigel Pharmaceuticals, Inc. | Pyrazole compounds and method for making and using the compounds |
| CN107872977B (en) | 2015-04-30 | 2021-07-09 | 拜耳制药股份公司 | Combination of an IRAK4 inhibitor and a BTK inhibitor |
| JP6720355B2 (en) * | 2015-06-24 | 2020-07-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Heteroaryl-substituted aminopyridine compounds |
| JP6720225B2 (en) | 2015-06-24 | 2020-07-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Heteroaryl-substituted aminopyridine compounds |
| UY36748A (en) | 2015-06-24 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | AMINOPIRIDINE COMPOUNDS REPLACED WITH HETEROARILO AS QUINASE INHIBITORS AND IRAK-4 MODULATORS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EP3322698A4 (en) | 2015-07-15 | 2019-01-09 | Aurigene Discovery Technologies Limited | INDAZOLE AND AZAINDAZOLE COMPOUNDS AS INHIBITORS OF IRAK-4 |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | AZA COMPOUNDS SUBSTITUTED AS INHIBITORS OF IRAQ-4 |
| WO2017021969A1 (en) | 2015-08-04 | 2017-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Pyrazole pyrimidine derivative and uses thereof |
| DK3331879T3 (en) | 2015-08-04 | 2020-08-10 | Rigel Pharmaceuticals Inc | BENZAZOLE COMPOUNDS AND METHODS OF PREPARATION AND USE OF THE COMPOUNDS |
| US10988482B2 (en) | 2015-08-13 | 2021-04-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | IRAK4 inhibitor and use thereof |
| KR102048719B1 (en) | 2015-08-13 | 2019-11-26 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | IRAK4 inhibitors and uses thereof |
| BR112018002071A2 (en) | 2015-08-13 | 2018-09-18 | Pfizer | fused bicyclic heteroaryl or aryl compounds |
| SI3341367T1 (en) | 2015-08-27 | 2021-05-31 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators |
| EP3350177B1 (en) | 2015-09-18 | 2021-07-07 | Merck Patent GmbH | Heteroaryl compounds as irak inhibitors and uses thereof |
| RU2743360C2 (en) | 2015-09-18 | 2021-02-17 | Мерк Патент Гмбх | Heteroaryl compounds as irak inhibitors and use thereof |
| GB201518456D0 (en) | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| WO2017108744A1 (en) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Novel substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| WO2017108723A2 (en) | 2015-12-22 | 2017-06-29 | F. Hoffmann-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| US11427561B2 (en) | 2016-01-20 | 2022-08-30 | Biogen Ma Inc. | IRAK4 inhibiting agents |
| MA44759B1 (en) | 2016-04-29 | 2024-01-31 | Bayer Pharma AG | POLYMORPH FORM OF N-(6-(2-HYDROXYPROPAN-2-YL)-2-[2-(METHYLSULFONYL)ETHYL]-2H-INDAZOL-5-YL)-6-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDE |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017207385A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted 3-methylindazoles, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments |
| EP3475263B1 (en) | 2016-06-27 | 2022-12-28 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors |
| EP4212523A1 (en) | 2016-10-26 | 2023-07-19 | Rigel Pharmaceuticals, Inc. | Pyrazole amide compounds as irak inhibitors |
| CN109890829B (en) | 2016-11-02 | 2022-07-15 | 豪夫迈·罗氏有限公司 | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators |
-
2017
- 2017-02-16 JO JOP/2018/0011A patent/JOP20180011A1/en unknown
-
2018
- 2018-02-05 TW TW110124807A patent/TWI790674B/en active
- 2018-02-05 TW TW107103929A patent/TWI733982B/en active
- 2018-02-05 TW TW111148495A patent/TW202340194A/en unknown
- 2018-02-14 BR BR102018002879A patent/BR102018002879A2/en active Search and Examination
- 2018-02-15 AU AU2018221812A patent/AU2018221812B2/en active Active
- 2018-02-15 PE PE2019001681A patent/PE20191540A1/en unknown
- 2018-02-15 JP JP2019543909A patent/JP6924267B2/en active Active
- 2018-02-15 SG SG11201906763RA patent/SG11201906763RA/en unknown
- 2018-02-15 EP EP18708796.0A patent/EP3583105B1/en active Active
- 2018-02-15 CR CR20190373A patent/CR20190373A/en unknown
- 2018-02-15 SM SM20240146T patent/SMT202400146T1/en unknown
- 2018-02-15 IL IL267979A patent/IL267979B/en unknown
- 2018-02-15 KR KR1020197026476A patent/KR102337055B1/en active Active
- 2018-02-15 UA UAA201908592A patent/UA124548C2/en unknown
- 2018-02-15 FI FIEP18708796.0T patent/FI3583105T3/en active
- 2018-02-15 MX MX2019009840A patent/MX2019009840A/en unknown
- 2018-02-15 CA CA3050148A patent/CA3050148A1/en active Pending
- 2018-02-15 MA MA47500A patent/MA47500B1/en unknown
- 2018-02-15 ES ES18708796T patent/ES2975767T3/en active Active
- 2018-02-15 US US15/898,095 patent/US10336762B2/en active Active
- 2018-02-15 PT PT187087960T patent/PT3583105T/en unknown
- 2018-02-15 CN CN201880012452.8A patent/CN110300754A/en active Pending
- 2018-02-15 SI SI201831068T patent/SI3583105T1/en unknown
- 2018-02-15 WO PCT/US2018/018431 patent/WO2018152368A1/en active Application Filing
- 2018-02-15 RS RS20240424A patent/RS65397B1/en unknown
- 2018-02-15 EA EA201991544A patent/EA201991544A1/en unknown
- 2018-02-15 DK DK18708796.0T patent/DK3583105T3/en active
- 2018-02-15 HU HUE18708796A patent/HUE065978T2/en unknown
- 2018-02-15 PL PL18708796.0T patent/PL3583105T3/en unknown
- 2018-02-15 LT LTEPPCT/US2018/018431T patent/LT3583105T/en unknown
- 2018-02-16 UY UY0001037608A patent/UY37608A/en not_active Application Discontinuation
- 2018-02-16 AR ARP180100369A patent/AR110935A1/en unknown
-
2019
- 2019-07-11 PH PH12019550128A patent/PH12019550128A1/en unknown
- 2019-08-14 CL CL2019002306A patent/CL2019002306A1/en unknown
- 2019-08-15 CO CONC2019/0008868A patent/CO2019008868A2/en unknown
- 2019-08-15 DO DO2019000214A patent/DOP2019000214A/en unknown
- 2019-08-16 MX MX2023010197A patent/MX2023010197A/en unknown
- 2019-08-18 SA SA519402462A patent/SA519402462B1/en unknown
- 2019-08-19 ZA ZA2019/05456A patent/ZA201905456B/en unknown
-
2021
- 2021-07-30 JP JP2021125416A patent/JP2021176902A/en not_active Withdrawn
-
2022
- 2022-09-08 AU AU2022228165A patent/AU2022228165A1/en not_active Abandoned
-
2023
- 2023-04-28 JP JP2023074711A patent/JP2023100791A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201907434RA (en) | Compositions and methods for immunooncology | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |